Cite
HARVARD Citation
Dixon, B. et al. (n.d.). Discordant CH50 and sC5b-9 in pharmacodynamic monitoring of eculizumab-treated patients with atypical hemolytic uremic syndrome. Molecular immunology. pp. 143-144. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Dixon, B. et al. (n.d.). Discordant CH50 and sC5b-9 in pharmacodynamic monitoring of eculizumab-treated patients with atypical hemolytic uremic syndrome. Molecular immunology. pp. 143-144. [Online].